This refresh
Data-driven refresh October 9, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,235 tickers); 1,693 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. GRND — Grindr Inc. · score 90.4
Software - Application · price $15.03 · 1Y $20.80 · 5Y $30.45 · 10Y $45.18
FCF $154m C · Rev +32.4% A · D/E Negative equity · P/E 32.0x B · PEG 1.13 B+
Why now. Grindr’s dominant position as the premier LGBTQ social networking app fuels relentless user expansion, driving 32.4% revenue growth and a healthy 18.7% profit margin that translate into $154 m of free‑cash‑flow. With a market cap of $2.6 b and a PE of 32, the stock is already priced for a 7% FCF growth rate—well below the 32% top‑line pace—meaning the upside is baked in. The thesis rests on the platform’s ability to keep compounding this high‑growth, high‑margin engine.
Moat. Grindr’s moat is its network effect within the global LGBTQ community; the app’s “Global Gayborhood” creates a sticky user base that drives both ad revenue and premium subscriptions, making switching costly for users who value the niche social graph and curated experience.
Risk. The stock trades at a PE of 32 despite a reverse‑DCF implied FCF growth of only 7%, far slower than the 32% revenue surge, suggesting the market is already discounting future slowdown; a miss on growth or margin compression would validate this pessimism and could push the price toward the 52‑week low of $9.73. A breach of the 52‑week low would confirm the bear case.
Horizon. 1-3 yr $20.80 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $30.45 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $45.18 if current growth sustains into durable earnings power.
2. HRMY — Harmony Biosciences Holdings, Inc. · score 88.5
Biotechnology · price $40.28 · 1Y $47.64 · 5Y $69.74 · 10Y $103.46
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 13.0x A- · PEG 0.38 A
Why now. HRMY’s bull case hinges on WAKIX’s dominant position in the U.S. narcolepsy market, where its novel mechanism fuels a 24.3% revenue growth and underpins an 18.9% profit margin. The Bull Rankings model awards a Quality‑Growth score of 88.5, with Growth as the strongest pillar, confirming the business’s compounding earnings power, while the cheap Value pillar (92) signals ample upside to the consensus $47.64 1‑yr target. The thesis rests on sustaining the high‑margin growth trajectory of WAKIX and its pipeline, which will keep compounding returns for years to come.
Moat. WAKIX’s unique histamine‑3 receptor antagonism creates a high barrier to entry, giving Harmony pricing power in the rare‑neurology niche and delivering an ROE of 18.1% driven by premium pricing and limited competition. This IP‑protected therapy locks in neurologists and sleep‑disorder clinics, making switching costly and preserving cash‑flow generation.
Risk. The bear case centers on the reverse‑DCF implied FCF growth of –15% in year 1, far below the trailing 24.3% revenue growth, indicating the market may be pricing in a sharp slowdown if pipeline trials falter. A modest debt‑to‑equity of 0.16 offers little cushion, and any setback in Phase 3 PWS or Phase 2 DM1 trials would compress margins and validate the pessimistic growth assumption. A missed trial would trigger a sell‑off and break the bull thesis.
Horizon. 1-3 yr $47.64 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.74 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $103.46 if current growth sustains into durable earnings power.
3. APP — AppLovin Corporation · score 88.3
Advertising Agencies · price $277.04 · 1Y $487.66 · 5Y $713.98 · 10Y $1,059
FCF $4.5b B · Rev +70.0% A · D/E 1.11 C+ · P/E 21.3x B · PEG 0.61 A-
Why now. The bull case hinges on MAX, AppLovin’s AI‑driven in‑app bidding platform, which is turbo‑charging publisher inventory value as the company rides a 70% YoY revenue growth wave. That growth is underpinned by a 64.6% profit margin and a robust $4.5B free‑cash‑flow generation engine, giving the business the cash to reinvest and outpace peers. The thesis rests on the Bull Rankings model’s strongest pillar – Growth – which signals that this compounding engine will keep compounding for years to come.
Moat. MAX creates a real‑time competitive auction that locks publishers into a network where every additional app adds data, improving bid efficiency and making it costly for rivals to replicate. Coupled with Adjust’s measurement suite, AppLovin embeds deep analytics into its customers’ marketing stacks, raising switching costs and cementing a durable edge.
Risk. The bear case points to the stock’s lofty valuation and volatility: a P/E of 21.3 sits above many sector peers, while a beta of 2.56 amplifies market swings, and a debt‑to‑equity of 1.11 adds leverage risk. If revenue growth stalls below the historic 70% and the implied 26% FCF growth in the reverse‑DCF fades faster, the high multiple could collapse, confirming the downside.
Horizon. 1-3 yr $487.66 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $713.98 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,059 if current growth sustains into durable earnings power.
4. OSCR — Oscar Health, Inc. · score 87.6
Healthcare Plans · price $33.37 · 1Y $35.40 · 5Y $51.83 · 10Y $76.89
FCF $4.4b B · Rev +27.5% A- · D/E 0.23 B · P/E 25.9x B · PEG 1.96 C+
Why now. Oscar Health’s tech‑driven Oscar platform and Campaign Builder are unlocking high‑margin growth in the individual, family and small‑group markets, fueling a revenue surge of 27.5% YoY while delivering a 3.6% profit margin and a stellar 34.3% ROE. Our Bull Rankings model gives OSCR an 87.6/100 quality‑growth score, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The thesis rests on the platform’s ability to keep scaling the same 27%+ revenue growth trajectory.
Moat. The Oscar platform creates a sticky digital health‑plan ecosystem that brokers and members can’t easily abandon, delivering pricing power that translates into a ROE of 34.3% by leveraging data‑driven enrollment and engagement tools that competitors would need years to replicate.
Risk. A lofty beta of 2.47 and a forward P/E of 25.9 signal that the market is pricing in premium growth; the Bull Rankings reverse‑DCF assumes year‑1 free‑cash‑flow growth will drop below 25%, far slower than the 27.5% revenue growth just reported, meaning any slowdown would crush the valuation. A breach of the 52‑week low ($10.69) would confirm the bearish view.
Horizon. 1-3 yr $35.40 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $51.83 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $76.89 if current growth sustains into durable earnings power.
5. DLO — DLocal Limited · score 87.2
Software - Infrastructure · price $15.23 · 1Y $18.80 · 5Y $27.53 · 10Y $40.83
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 22.4x B+ · PEG 0.65 A-
Why now. DLocal’s cross‑border payment platform for e‑commerce, streaming and ride‑hailing merchants is exploding, delivering 46.6% revenue growth YoY while keeping an 18% profit margin and a stellar 34.6% ROE. Our Bull Rankings model flags Growth as the strongest pillar (96), meaning the business can keep compounding on the back of its pay‑in/pay‑out suite, and the reverse‑DCF shows the market is pricing a slower –7% start‑up FCF growth than the 46.6% revenue surge just reported, leaving clear upside. The thesis rests on the platform’s ability to keep winning new global merchants and lock in that high‑margin cash flow.
Moat. The platform’s ability to ingest hundreds of alternative payment methods creates a high switching cost for merchants who need a single, compliant gateway for both cross‑border and local transactions, locking in revenue and enabling DLocal to command pricing power that fuels its >34% ROE. This network of payment options and the dLocal for Platforms suite cannot be replicated quickly, cementing a durable edge.
Risk. The market still values DLocal at a forward P/E of 22.4 despite its explosive growth, and the reverse‑DCF assumes an initial –7% FCF contraction, implying investors are wary of dilution and a potential slowdown. A sustained miss on revenue growth or a rise in dilution would validate the bearish view and crush the upside.
Horizon. 1-3 yr $18.80 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.53 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $40.83 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 87.2
Drug Manufacturers - Specialty & Generic · price $142.44 · 1Y $207.29 · 5Y $303.50 · 10Y $450.22
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 20.9x B+ · PEG 0.28 A
Why now. NBIX is poised to dominate the rare endocrine‑disorder market thanks to Orilissa and Oriahnn, whose combined sales are fueling a 34.4% revenue growth and a 20.9% profit margin. The business’s PE of 20.9 and a PEG of 0.28 underscore that earnings are expanding far faster than the price, making the current upside hinge on sustaining this high‑growth trajectory. The thesis rests on the ability to keep compounding revenue at the 30%+ rate delivered this year.
Moat. NBIX’s moat stems from its FDA‑approved, niche‑indication drugs—INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia—each protected by robust patents and serving patient populations with few alternatives, creating high switching costs. The 19.1% ROE reflects pricing power derived from being a category leader in these specialized therapies, which competitors cannot quickly replicate due to the long development cycles and regulatory hurdles.
Risk. The bear case centers on the price already assuming a slower growth path: the reverse‑DCF implies free‑cash‑flow expansion of only 7% in year 1, well below the trailing 34.4% revenue surge, suggesting the market may be under‑pricing a potential slowdown. A modest debt‑to‑equity of 0.12 offers little cushion if upcoming clinical trials for NBI‑1076986 or Osavampator falter, and a PE of 20.9 is elevated for a specialty biotech, making a valuation correction plausible. A missed trial or adverse regulatory outcome would trigger a sharp re‑rating.
Horizon. 1-3 yr $207.29 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $303.50 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $450.22 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 86.5
Semiconductors · price $229.28 · 1Y $328.72 · 5Y $481.27 · 10Y $713.94
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 29.0x B · PEG 0.28 A
Why now. NVIDIA’s Compute & Networking segment is cementing its role as the backbone of AI data centers, and that engine is still roaring. Revenue is exploding at +83.4% YoY, translating into a staggering 63.7% profit margin and an eye‑popping 84.2% ROE—the kind of cash‑generating power that compounds forever. The whole thesis rests on the relentless demand for its data‑center GPUs, which will keep the growth curve steep for years to come.
Moat. The moat lives in NVIDIA’s unrivaled GPU IP and the deep integration of its AI software stack into the Compute & Networking platform, locking in hyperscale cloud providers and enterprise customers who face massive switching costs. Its 84.2% ROE reflects pricing power that stems from being the de‑facto standard for accelerated AI workloads, a position competitors can’t replicate overnight.
Risk. The stock trades at a lofty P/E of 29 and a beta of 2.22, meaning any slowdown in AI spend or a broader market pullback will hammer the price hard. Our reverse‑DCF shows the market assumes only a 48% FCF growth rate in year 1, well below the 83.4% revenue surge just delivered—if growth decelerates further, the valuation collapses. A breach of the 48% growth assumption would confirm the bear case and bust the bull thesis.
Horizon. 1-3 yr $328.72 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $481.27 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $713.94 if current growth sustains into durable earnings power.
8. ADMA — ADMA Biologics, Inc. · score 86.3
Biotechnology · price $10.36 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $116m C · Rev +19.6% B+ · D/E 0.50 B · P/E 14.8x A- · PEG 0.80 A-
Why now. Biotechnology · market cap $2.3b. Down 49% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.80 — paying under fair value for the growth rate. 4 sell-side analysts publish a mean 1-yr target of $17.00 (implying +64% upside).
Moat. Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk. Down 49% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $17.00 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
9. FICO — Fair Isaac Corporation · score 86.3
Software - Application · price $667.58 · 1Y $1,113 · 5Y $1,630 · 10Y $2,418
FCF $961m C+ · Rev +15.9% B+ · D/E Negative equity · P/E 19.3x B+ · PEG 0.67 A-
Why now. Software - Application · market cap $14.4b. Down 64% from 52-week high of $1858.91 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.67 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $1,113 (implying +67% upside).
Moat. Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 118% of net income — earnings translate cleanly into cash. Software economics — recurring revenue, embedded customer workflows, and high gross margin all compound the moat once a base account is won. Switching costs are the lever.
Risk. Down 64% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $1,113 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $1,630 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $2,418 if current growth sustains into durable earnings power.
10. ADBE — Adobe Inc. · score 85.4
Software - Application · price $242.27 · 1Y $275.06 · 5Y $402.72 · 10Y $597.41
FCF $10.6b A- · Rev +10.5% B · D/E 0.58 C+ · P/E 13.5x A- · PEG 0.58 A-
Why now. Adobe's entrenched position in digital content creation and customer experience is significantly undervalued, presenting a compelling opportunity for long-term investors. Despite delivering a robust 28% profit margin and generating $10.6b in free cash flow over the past twelve months, the stock trades at a remarkably low 13.5x P/E (TTM), with a PEG ratio of just 0.58. Our Bull Rankings model assigns ADBE a strong Quality-growth score of 85.4/100, with its Quality pillar scoring 92, underscoring the fundamental strength and durable returns from its Digital Media and Digital Experience segments. The market is failing to fully appreciate the compounding effect of these highly profitable, mission-critical platforms.
Moat. Adobe's competitive moat is built on the indispensable nature of its Digital Media and Digital Experience platforms, which are deeply embedded in the workflows of photographers, video editors, graphic designers, marketers, and enterprises worldwide. The high switching costs associated with its integrated content creation and customer experience management solutions create a sticky customer base. This category leadership and recurring revenue model enable its exceptional 61.9% Return on Equity, reflecting strong pricing power and efficient capital allocation that competitors struggle to replicate.
Risk. Skeptics argue that while Adobe's valuation appears cheap, the market is correctly pricing in a deceleration of its core business growth. Despite a 10.5% revenue growth (FY YoY), our reverse DCF analysis shows the current price implies free-cash-flow growth starting at approximately -2% in year one, fading to 3% by year ten – a rate significantly lower than its recent top-line expansion. This concern is reflected in our Bull Rankings model, where the Growth pillar, at 80, is the softest component of ADBE's otherwise strong Quality-growth score of 85.4/100. A continued slowdown in new customer acquisition within its Digital Media segment or increased competitive pressure in the Digital Experience market would validate this pessimistic outlook.
Horizon. 1-3 yr $275.06 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $402.72 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $597.41 if current growth sustains into durable earnings power.
11. INOD — Innodata Inc. · score 83.7
Information Technology Services · price $62.04 · 1Y $122.75 · 5Y $179.72 · 10Y $266.60
FCF $184m C · Rev +47.6% A · D/E 0.02 A- · P/E 48.1x C+ · PEG 0.87 B+
Why now. The bull case hinges on Innodata’s AI‑centric Digital Data Solutions (DDS) platform, which is riding a near‑term explosion of AI model training demand. The business delivered 47.6% YoY revenue growth, translates into a robust 14.7% profit margin and generated $184 m of free cash flow—all on a $2.1 bn market cap—fueling a compounding engine that can sustain double‑digit returns. The thesis rests on the continuation of this high‑growth engine as AI adoption deepens across enterprises.
Moat. Innodata’s moat stems from the DDS segment’s proprietary AI‑training data pipelines, which embed costly labeling, curation and compliance processes that customers cannot quickly replicate. This creates high switching costs for AI developers and insurers that rely on Synodex’s structured medical data, while the company’s 37.8% ROE reflects pricing power derived from being a trusted data‑engineer for mission‑critical AI deployments.
Risk. The bear case points to the stock’s lofty valuation—PE 48.1×—and a beta of 2.98, indicating extreme price volatility. Moreover, the Bull Rankings model’s reverse‑DCF assumes free‑cash‑flow growth of only 10% in year 1, far below the 47.6% revenue surge just reported, suggesting the market may be under‑pricing growth risk. A sustained slowdown in AI spending or a missed margin target would validate this risk and crush the upside.
Horizon. 1-3 yr $122.75 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $179.72 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $266.60 if current growth sustains into durable earnings power.
12. FIVE — Five Below, Inc. · score 83
Specialty Retail · price $214.73 · 1Y $310.48 · 5Y $454.57 · 10Y $674.32
FCF $599m C+ · Rev +22.9% A- · D/E 0.82 B · P/E 19.2x B · PEG 0.98 B+
Why now. The bull case hinges on Five Below’s rapid expansion of its personalized living‑space merchandise – lamps, posters, plush items and accent furniture – which fuels a compounding revenue engine. The business just delivered 22.9% FY revenue growth, translates into a healthy 11.7% profit margin and a stellar 28.3% ROE, all while the Bull Rankings model awards an 83/100 quality‑growth score with Growth as its strongest pillar. That growth engine, anchored in a category where teens and budget‑conscious shoppers continually refresh décor, should keep compounding for years to come.
Moat. Five Below’s moat lives in its category‑leadership on low‑price, trend‑driven home décor and novelty accessories that command frequent repeat purchases; the SKU mix and store footprint lock in a captive teen‑and‑young‑adult shopper base that cannot be replicated overnight. The 28.3% ROE reflects pricing power and efficient inventory turnover in this niche, while a modest 0.82 debt‑to‑equity ratio gives the firm financial flexibility to reinvest in new product lines.
Risk. The bear case centers on the fact that the market is pricing in slower future growth – the reverse DCF implies only a 10% cash‑flow expansion in year 1, well below the 22.9% revenue surge just reported – and the stock trades at a 19.2× forward P/E, which is elevated for a specialty retailer. If margin pressure intensifies or the novelty‑decor segment stalls, the high multiple could collapse. A sustained dip in profit margin below the current 11.7% would confirm the downside.
Horizon. 1-3 yr $310.48 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $454.57 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $674.32 if current growth sustains into durable earnings power.
13. CARG — CarGurus, Inc. · score 82.4
Internet Content & Information · price $28.85 · 1Y $41.27 · 5Y $60.43 · 10Y $89.64
FCF $291m C · Rev +13.7% B+ · D/E 0.70 B · P/E 15.3x B+ · PEG 0.63 A-
Why now. CarGurus’ Digital Deal platform is unlocking a new, high‑margin revenue stream by letting shoppers start purchases online, and it’s already fueling a 13.7% YoY revenue growth while the business delivers an 18.2% profit margin and a stellar 53.5% ROE. The combination of a cheap‑ish valuation (our model’s Value pillar at 79) and a buy‑back signal means the market is under‑pricing this growth engine. The thesis rests on the Digital Deal’s ability to keep compounding that margin‑rich growth.
Moat. The moat comes from CarGurus’ integrated marketplace that locks dealers into a subscription‑based network and ties them to the Digital Deal workflow, creating switching costs for both dealers and shoppers. Its 53.5% ROE reflects pricing power that stems from being the go‑to platform for a large, engaged car‑shopping audience, a position competitors can’t replicate quickly without building a comparable dealer base.
Risk. The bear case hinges on the reverse‑DCF’s implied free‑cash‑flow growth of –5% in year 1, a stark contrast to the 13.7% revenue growth just delivered, suggesting the market is already pricing in a slowdown that could erode the 18.2% margin. A sustained dip in growth would push the P/E of 15.3 higher relative to peers and could trigger a sell‑off, especially with a beta of 1.22 amplifying market swings. Confirmation would be a miss on the next quarter’s revenue growth and a widening of the debt‑to‑equity ratio above 0.7.
Horizon. 1-3 yr $41.27 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $60.43 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $89.64 if current growth sustains into durable earnings power.
14. MU — Micron Technology, Inc. · score 82.1
Semiconductors · price $1029.00 · 1Y $1,555 · 5Y $2,277 · 10Y $3,378
FCF $59.0b A · Rev +256.3% A · D/E 0.04 A- · P/E 13.8x A- · PEG 0.16 A
Why now. Micron’s explosive 256.3% revenue growth is being driven by its Cloud Memory and Core Data Center Business Units, where demand for CXL‑based and high‑bandwidth memory is surging. Coupled with a razor‑thin 13.8× P/E, a rock‑solid 63.8% profit margin and a 61.4% ROE, the stock is priced for a continuation of hyper‑growth rather than a one‑off spike. The thesis rests on the persistence of data‑center memory spend, which should keep compounding revenue at double‑digit rates for years to come.
Moat. Micron’s moat comes from its deep integration in data‑center and cloud infrastructure through proprietary CXL‑based and high‑bandwidth memory modules, which command premium pricing and lock in long‑term contracts with hyperscale cloud providers. The resulting 61.4% ROE reflects pricing power that rivals cannot replicate quickly because of Micron’s advanced process technology and extensive IP portfolio across its four business units.
Risk. The stock’s high beta of 2.23 makes it vulnerable to a tech‑cycle pullback, and the Bull Rankings model’s reverse‑DCF shows the market only assumes a 25% FCF growth start‑rate—far below the 256.3% revenue surge just delivered—so any slowdown in memory demand would expose the valuation to a sharp correction. A breach of the 52‑week low ($179.61) or a sustained drop in profit margin would confirm the bear case.
Horizon. 1-3 yr $1,555 (analyst consensus (n=46)) — fundamentals + valuation re-rating. 5 yr $2,277 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $3,378 if current growth sustains into durable earnings power.
15. PGY — Pagaya Technologies Ltd. · score 82
Software - Infrastructure · price $18.22 · 1Y $28.82 · 5Y $42.19 · 10Y $62.59
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 13.2x A · PEG 0.03 A
Why now. Pagaya’s flagship Decline Monetization platform is unlocking a hidden pool of credit by automatically routing rejected loan applications to its AI‑driven network, fueling a 25.6% YoY revenue surge. The business trades at a modest PE of 13.2 and generates $252 m of free cash flow, delivering a ROE of 19.5% that validates the Bull Rankings model’s strongest pillar – Value – at 90. The thesis rests on scaling this AI‑powered loan‑recovery engine across U.S. financial institutions, compounding growth well beyond the market’s current pricing.
Moat. The Decline Monetization engine creates a high‑switching‑cost ecosystem: partners hand over rejected applications and receive incremental approvals, locking in data flows that competitors cannot replicate without building a comparable AI model and partner network. This proprietary AI layer drives pricing power, evident in the 19.5% ROE, and entrenches Pagaya’s position as the go‑to partner for loan‑originators seeking to monetize declines.
Risk. Pagaya’s beta of 5.52 signals extreme price volatility, and its debt‑to‑equity of 1.34 adds financial leverage risk. Moreover, the Bull Rankings model’s reverse DCF shows the market assumes a starting free‑cash‑flow contraction of –7% versus the actual 25.6% revenue growth, indicating pessimism baked into the price. A sustained slowdown in loan‑originations or a failure to expand the network would confirm this bearish view and crush the upside.
Horizon. 1-3 yr $28.82 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $42.19 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $62.59 if current growth sustains into durable earnings power.
16. DECK — Deckers Outdoor Corporation · score 81.9
Footwear & Accessories · price $82.89 · 1Y $120.41 · 5Y $176.29 · 10Y $261.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.21 A- · P/E 11.7x A- · PEG 1.01 B+
Why now. The HOKA performance‑footwear franchise is accelerating as consumers chase premium running and trail experiences, driving 9.8% revenue growth and a robust 18.4% profit margin. With a modest PE of 11.7, the market still undervalues the cash‑generating engine, and the compounding power of the HOKA brand underpins a multi‑year upside.
Moat. Deckers leverages category leadership in premium casual and performance footwear – UGG dominates the luxury‑loungewear niche while HOKA commands the high‑performance running segment – delivering pricing power that fuels a staggering ROE of 42.6%. Its direct‑to‑consumer and selective retail network locks in brand‑aware shoppers, creating a switch‑cost barrier competitors struggle to breach.
Risk. The Bull Rankings model flags a slowing growth narrative: the reverse‑DCF assumes a negative -3% FCF growth in year 1, far below the trailing 9.8% revenue growth, suggesting the market may be pricing in a near‑term slowdown. A beta of 1.12 amplifies downside in a volatile equity environment, and the stock sits 33% below its 52‑week high of $122.29, limiting upside if momentum stalls.
Horizon. 1-3 yr $120.41 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $176.29 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $261.52 if current growth sustains into durable earnings power.
17. DXCM — DexCom, Inc. · score 81.5
Medical Devices · price $84.11 · 1Y $96.23 · 5Y $140.89 · 10Y $209.00
FCF $1.4b C+ · Rev +15.6% B+ · D/E 0.53 B · P/E 33.4x C+ · PEG 2.11 C
Why now. DexCom’s G7 platform, now the market‑leading CGM for both Type 1 and insulin‑using Type 2 diabetics, is scaling rapidly – revenue is climbing 15.6% YoY while profit margins sit at a healthy 20.1% and free cash flow hits $1.4 B. Coupled with a 26‑analyst consensus price of $96.23, the stock is primed to ride the next wave of CGM adoption as insurers broaden coverage. The thesis hinges on the G7’s continued market share expansion, which fuels compounding earnings growth.
Moat. DexCom’s moat stems from its integrated CGM ecosystem – the G7 sensor, the Share remote‑monitoring service, and the Follow app – all prescribed by endocrinologists and embedded in diabetes care pathways. This lock‑in drives a ROE of 38.5%, reflecting pricing power that stems from being the default CGM for both new and existing patients, a position rivals cannot replicate quickly due to regulatory hurdles and the need for extensive clinical data.
Risk. The stock trades at a lofty PE of 33.4 and a beta of 1.48, meaning any slowdown in CGM adoption or a pricing squeeze could knock the valuation sharply. A modest debt‑to‑equity of 0.53 also leaves limited headroom if the company needs to fund new product rollouts. A sustained dip in revenue growth below the current 15.6% would validate the risk and likely trigger a sell‑off.
Horizon. 1-3 yr $96.23 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $140.89 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $209.00 if current growth sustains into durable earnings power.
18. PODD — Insulet Corporation · score 81.3
Medical Devices · price $135.28 · 1Y $170.96 · 5Y $250.30 · 10Y $371.30
FCF $294m C · Rev +29.4% A- · D/E 0.67 C+ · P/E 25.3x B · PEG 1.06 B+
Why now. Medical Devices · market cap $9.4b. Down 62% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +29% — in hypergrowth territory. 23 sell-side analysts rate this a Buy with a mean 1-yr target of $170.96 (implying +26% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Down 62% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $170.96 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $250.30 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $371.30 if current growth sustains into durable earnings power.
19. NFLX — Netflix, Inc. · score 81.2
Entertainment · price $70.30 · 1Y $92.55 · 5Y $135.50 · 10Y $201.01
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B+ · P/E 22.1x B · PEG 1.22 B
Why now. Netflix’s global streaming platform is the engine, and its 16% revenue growth combined with a 28.2% profit margin and a staggering 45.3% ROE prove the business can compound cash at a premium. Our Bull Rankings model rates the stock at an 81.2 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its cash‑generating engine. The thesis rests on the ability to keep expanding subscriber minutes and upsell premium tiers, which will keep the compounding engine humming.
Moat. Netflix’s moat lives in its proprietary recommendation algorithm and deep, globally‑licensed content library that lock in members across TVs, set‑top boxes and mobiles. The 45.3% ROE reflects pricing power derived from being the category leader in on‑demand streaming, a lever competitors can’t replicate quickly without massive content spend and data infrastructure.
Risk. The stock trades at a forward P/E of 22.1 and a beta of 1.61, indicating both valuation premium and heightened volatility; a slowdown in revenue growth below the historical 16% or margin erosion would make the price unjustified. Additionally, a debt‑to‑equity of 0.55 adds leverage risk if cash flow falters. A confirmed dip in quarterly revenue growth would trigger the bear case and bust the bull thesis.
Horizon. 1-3 yr $92.55 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $135.50 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $201.01 if current growth sustains into durable earnings power.
20. EXLS — ExlService Holdings, Inc. · score 80.6
Information Technology Services · price $36.79 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $275m C · Rev +13.6% B+ · D/E 0.57 C+ · P/E 23.3x B+ · PEG 0.96 B+
Why now. EXLS is poised to capture expanding AI‑driven digital operations in the insurance market, where its claims‑management and underwriting‑support platforms lock in long‑term contracts. The business is delivering 13.6% YoY revenue growth, 11.2% profit margin and generates $275 m of free cash flow, all on a 25.9% ROE, giving the stock a clear compounding engine that will keep earnings accelerating for years to come. The thesis rests on the durability of these high‑margin AI services that continue to win new business.
Moat. The moat comes from deep integration of EXLS’s analytics into insurers’ core processes—claims, underwriting and policy servicing—creating costly switching for carriers. This stickiness fuels a 25.9% ROE, reflecting pricing power that stems from category leadership in AI‑enabled insurance solutions, which rivals cannot replicate quickly.
Risk. The bear case hinges on the market pricing in slower growth than the company just delivered: the reverse‑DCF implies only 8% cash‑flow growth in year 1, well below the 13.6% revenue growth rate, so any deceleration would crush the valuation. A still‑elevated P/E of 23.3 and a debt‑to‑equity of 0.57 add leverage risk, and a modest beta of 0.84 means the stock won’t be insulated from broader tech‑service downturns. A miss on next‑year growth would confirm the downside.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
21. GMED — Globus Medical, Inc. · score 80.5
Medical Devices · price $74.65 · 1Y $100.92 · 5Y $147.76 · 10Y $219.19
FCF $746m C+ · Rev +16.7% B+ · D/E 0.02 A- · P/E 19.1x B+ · PEG 1.49 B
Why now. Medical Devices · market cap $10.0b. Down 26% from 52-week high of $101.40 — deep drawdown territory. Revenue growing +17%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $100.92 (implying +35% upside).
Moat. Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 139% of net income — earnings translate cleanly into cash.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $100.92 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $147.76 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $219.19 if current growth sustains into durable earnings power.
22. GOOG — Alphabet Inc. · score 80.4
Internet Content & Information · price $347.86 · 1Y $420.36 · 5Y $615.45 · 10Y $912.98
FCF $53.3b A · Rev +20.1% A- · D/E 0.19 A- · P/E 17.5x B · PEG 1.21 B
Why now. Alphabet’s engine is its unrivaled ad‑driven ecosystem anchored by Search and YouTube, now turbo‑charged by AI‑enhanced ad products that keep advertisers locked in. The business is delivering 20.1% revenue growth YoY, converting that into a staggering 54.8% profit margin and $53.3 billion of free cash flow, all while trading at a modest PE of 17.5. The whole thesis rests on the compounding power of AI‑augmented ads and cloud services that will keep the growth engine humming for years to come.
Moat. Google’s Search and YouTube platforms create a two‑sided network effect: users generate data that refines ad relevance, while advertisers fund the platform, making it prohibitively costly for rivals to replicate. This moat fuels an ROE of 38.1%, reflecting pricing power that stems from category leadership in digital advertising and the stickiness of enterprise cloud contracts in the Google Cloud segment.
Risk. The Bull Rankings model assumes a reverse‑DCF growth rate of 54% in year 1, far above the trailing 20.1% revenue growth, meaning the market has already baked in aggressive optimism; a slowdown to the historical pace would crush the valuation. Coupled with a beta of 1.21 and a PE that, while reasonable, still reflects premium pricing, any miss on AI ad performance or cloud win‑rate would trigger a sell‑off. The bear case is confirmed if quarterly revenue growth falls below 15% and the stock slides back toward its 52‑week low of $236.69.
Horizon. 1-3 yr $420.36 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $615.45 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $912.98 if current growth sustains into durable earnings power.
23. KTB — Kontoor Brands, Inc. · score 80
Apparel Manufacturing · price $65.62 · 1Y $97.50 · 5Y $142.75 · 10Y $211.76
FCF $422m C · Rev +34.3% A · D/E 2.06 C · P/E 16.0x B · PEG 1.89 C+
Why now. The Bull Rankings model gives KTB a Quality‑growth score of 80, with Quality as the strongest pillar, and the Wrangler/Lee denim franchise is delivering 34.3% revenue growth YoY while generating $422 m of free cash flow and a stellar ROE of 43.3%. That combination of high‑margin, high‑growth apparel and cash generation makes the stock a premium growth engine, and the thesis hinges on the brand’s ability to keep compounding that top‑line momentum.
Moat. KTB’s moat lives in its entrenched Wrangler and Lee denim platforms, sold through mass merchants, specialty stores and a fast‑growing direct‑to‑consumer channel that locks in repeat purchases and limits price competition. The 43.3% ROE reflects pricing power from category leadership in workwear and casual denim, a lever that rivals can’t quickly replicate without comparable brand equity and distribution depth.
Risk. The reverse DCF shows the market pricing in a starting free‑cash‑flow growth of –11% that would have to climb to just 3% by year 10, well below the recent 34.3% revenue surge, implying a steep deceleration risk; coupled with a debt‑to‑equity of 2.06, any slowdown in growth or margin compression could force the stock toward its 52‑week low of $56.19. A breach of the –11% growth assumption would confirm the bear case and invalidate the upside thesis.
Horizon. 1-3 yr $97.50 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $142.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $211.76 if current growth sustains into durable earnings power.
24. CPAY — Corpay, Inc. · score 78.2
Software - Infrastructure · price $397.92 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +13.9% B+ · D/E 2.75 D · P/E 24.2x B+ · PEG 0.77 A-
Why now. Corpay’s corporate payments platform—especially its cross‑border spend‑management and virtual‑card suite—is scaling at a 13.9% revenue growth YoY while delivering a 22.7% profit margin and a stellar 29.2% ROE. The Bull Rankings model flags a Quality score of 88, confirming the business’s high‑margin, cash‑generating engine, and the market already rewards that with a PEG of 0.77. The thesis rests on the persistence of corporate expense digitization, which should keep compounding earnings for years to come.
Moat. Corpay’s moat lives in its integrated AP‑modernization and virtual‑card ecosystem, which locks large enterprises into a single spend‑control platform and creates high switching costs. That pricing power fuels a 29.2% ROE, as customers pay a premium for real‑time compliance, fuel‑toll integration, and automated reimbursement workflows that competitors can’t replicate quickly.
Risk. The stock trades at a forward‑looking P/E of 24.2 despite a reverse‑DCF that assumes only ~3% free‑cash‑flow growth—far below the 13.9% revenue expansion just delivered—suggesting the market may be over‑optimistic about future growth. A debt‑to‑equity ratio of 2.75 adds leverage risk if cash conversion slows, and any slowdown in corporate spend could compress margins and trigger a valuation correction.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
25. SE — Sea Limited · score 77.9
Internet Retail · price $95.25 · 1Y $154.93 · 5Y $226.84 · 10Y $336.49
FCF $4.5b B · Rev +36.4% A · D/E 0.32 A- · P/E 36.8x C · PEG 0.89 B+
Why now. Sea Limited’s growth engine is its Shopee marketplace, which is still expanding at a blistering 36.4% YoY revenue growth while delivering a solid 6.9% profit margin and generating $4.5 B of free cash flow. That triple‑digit top‑line expansion fuels compounding earnings that can keep the stock climbing well beyond its current level. The thesis hinges on Shopee’s ability to keep scaling in Southeast Asia and Latin America, turning today’s momentum into a multi‑year growth runway.
Moat. Shopee’s integrated ecosystem—mobile‑first marketplace, in‑house logistics, and the Monee payments suite—creates high switching costs for both merchants and consumers, locking them into Sea’s platform. Garena adds a network‑effect layer by tying gamers to a single digital entertainment hub, reinforcing cross‑sell opportunities and deepening user stickiness that rivals can’t replicate quickly.
Risk. The Bull Rankings model flags diluting shareholders, and the stock trades at a lofty PE of 36.8 with a beta of 1.55, indicating sensitivity to market swings. More importantly, the reverse‑DCF shows the market is pricing in a modest 10% year‑1 FCF growth, far below the 36.4% revenue surge just reported; any slowdown toward that modest pace would crush the upside. A sustained deceleration or a large equity issuance would confirm the bear case.
Horizon. 1-3 yr $154.93 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $226.84 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $336.49 if current growth sustains into durable earnings power.
26. CPRT — Copart, Inc. · score 77.7
Specialty Business Services · price $27.32 · 1Y $39.00 · 5Y $57.10 · 10Y $84.70
FCF $1.3b C+ · Rev +9.7% B · D/E 0.01 A · P/E 17.6x A- · PEG 2.76 C
Why now. Copart’s global virtual‑bidding platform locks in a relentless cash‑flow engine by letting insurers, dealers and fleet owners sell vehicles online across 12 countries, delivering a 31.8% profit margin, $1.3 B of free cash flow and 9.7% revenue growth YoY. Our Bull Rankings model crowns Quality at 88 – the strongest pillar – confirming the business’s operational excellence, and the price target hinges on that high‑margin, high‑cash engine compounding year after year.
Moat. The third‑generation internet auction technology creates a sticky ecosystem of sellers and buyers who must invest in Copart’s proprietary bidding interface, generating switching costs that protect margins. With a debt‑to‑equity of just 0.01 and a ROE of 16.2%, Copart converts its pricing power in vehicle remarketing into superior returns that rivals can’t easily replicate.
Risk. The reverse‑DCF shows the market pricing an 11% FCF growth start versus the actual 9.7% revenue growth, hinting that optimism is already baked in; a slowdown to the model’s 3% long‑run rate would crush the upside. A PEG of 2.76 also flags that the current valuation may be stretched if growth decelerates, and a breach of the 52‑week low ($26.39) would confirm the bear case.
Horizon. 1-3 yr $39.00 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $57.10 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $84.70 if current growth sustains into durable earnings power.
27. MELI — MercadoLibre, Inc. · score 77.4
Internet Retail · price $1889.85 · 1Y $2,276 · 5Y $3,332 · 10Y $4,943
FCF $12.4b A- · Rev +46.0% A · D/E 1.69 C+ · P/E 51.4x D · PEG 1.01 B+
Why now. MercadoLibre's integrated ecosystem, particularly the synergy between its Mercado Libre Marketplace and Mercado Pago financial technology platform, drives exceptional growth. Our model's 'Growth' pillar, scoring 96/100, confirms this momentum, reflecting the company's ability to consistently expand revenue at +46% TTM YoY. With $12.4B in TTM free cash flow and a 5.3% profit margin, MELI is compounding effectively, and the Bull Rankings model's reverse DCF implies FCF growth of just -7% in year 1, significantly lower than actual revenue growth, suggesting deep pessimism is priced into the current valuation.
Moat. MELI's durable edge stems from the powerful network effects generated by its Mercado Libre Marketplace and the sticky, integrated financial technology services offered through Mercado Pago. This comprehensive platform, including Mercado Fondo and Mercado Credito, creates high switching costs for users across Brazil, Mexico, and Argentina. A robust 23.8% Return on Equity reflects the pricing power and efficient capital allocation derived from this category leadership, a mechanism reinforced by our model's signal of 'Durable high returns'.
Risk. Skeptics point to MELI's elevated P/E of 51.4 and a debt-to-equity ratio of 1.69, arguing that any deceleration in its blistering growth could severely impact valuation. While our model's 'Value' pillar, at 64/100, is its softest, it still ranks MELI on the cheap side against peers and history, but it highlights the market's sensitivity to future growth rates. Intense competition in the 'Internet Retail' and financial technology sectors could pressure the current 5.3% profit margin; a sustained drop in revenue growth below the current 46% TTM YoY would confirm the bear case.
Horizon. 1-3 yr $2,276 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $3,332 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,943 if current growth sustains into durable earnings power.
28. LLY — Eli Lilly and Company · score 77.3
Drug Manufacturers - General · price $1179.27 · 1Y $1,330 · 5Y $1,947 · 10Y $2,889
FCF $13.6b A- · Rev +49.6% A · D/E 1.62 C · P/E 39.6x C+ · PEG 1.13 B+
Why now. Drug Manufacturers - General · market cap $1.1T. 9% off the 52-week high of $1292.65. Revenue growing +50% — in hypergrowth territory. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $1,330 (implying +13% upside).
Moat. Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 13.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $1,330 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $1,947 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $2,889 if current growth sustains into durable earnings power.
29. MLI — Mueller Industries, Inc. · score 77.1
Metal Fabrication · price $60.71 · 1Y $69.82 · 5Y $102.22 · 10Y $151.63
FCF $666m C+ · Rev +14.8% B+ · D/E 0.01 A · P/E 15.8x A- · PEG 3.41 D
Why now. The bull case hinges on Mueller’s dominant Piping Systems franchise, which supplies copper tubes and fittings to the booming U.S. plumbing and refrigeration markets. That franchise rides a 14.8% revenue growth rate, a 18.2% profit margin and a rock‑solid ROE of 24%, all while the Bull Rankings model awards a 77.1/100 quality‑growth score with Growth as its strongest pillar. The combination of high margins and compounding top‑line growth means earnings will keep compounding, and the stock’s current price already embeds a modest 13% year‑1 FCF growth — in line with the trailing revenue pace — leaving upside room as the business scales.
Moat. Mueller’s moat lives in its integrated supply chain for copper, brass and aluminum pipe components, sold directly to wholesalers and OEMs that require strict compliance and low‑failure parts. The Piping Systems segment’s pricing power stems from category leadership in copper tubing, which underpins the 24% ROE and forces competitors to incur higher material and certification costs to win the same contracts. This cost advantage and the entrenched distribution network to building‑material retailers and RV manufacturers are not easily replicated.
Risk. The bear case centers on the softest pillar in our model — Value — which, despite a 66 score, signals that the stock is priced ahead of its peers and its own historical P/E range. At a forward‑looking P/E of 15.8, any slowdown in the 14.8% revenue growth trajectory would compress margins and push the valuation into the high‑multiple zone. A near‑term earnings miss or a dip in the construction‑related plumbing market would confirm the risk, driving the price back toward the 52‑week low of $48.27.
Horizon. 1-3 yr $69.82 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $102.22 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $151.63 if current growth sustains into durable earnings power.
30. YUMC — Yum China Holdings, Inc. · score 77.1
Restaurants · price $42.92 · 1Y $61.91 · 5Y $90.65 · 10Y $134.47
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 15.3x B+ · PEG 0.93 B+
Why now. Yum China’s dominance in the fast‑food market, anchored by its KFC and Pizza Hut restaurant network, fuels a compounding revenue engine that is already delivering 8.8% YoY growth while generating $940m of free cash flow and a solid 18.2% ROE. Our Bull Rankings model awards a Quality‑growth score of 77.1, with Quality as the strongest pillar, confirming the business’s durable earnings power. The thesis rests on the continued roll‑out of digital ordering and delivery across these iconic brands, which should keep the growth engine humming.
Moat. The KFC and Pizza Hut concepts give Yum China a massive, city‑wide footprint that couples high‑traffic locations with a proprietary online delivery platform, creating a lock‑in of urban diners who value convenience. This scale translates into pricing power that underpins the current 18.2% ROE, a level unattainable for smaller, fragmented competitors.
Risk. The biggest headwind is the modest profit margin of only 7.8%, which leaves little cushion if input costs rise or competitive discounting intensifies, and the 52‑week low of $39.72 shows the stock can retreat sharply. A slowdown in revenue growth below the current 8.8% would pressure the P/E of 15.3 and could trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $61.91 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $90.65 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $134.47 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.